Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center

Background: Colorectal cancer (CRC) is the third most common cancer in Europe, with an annual increase in incidence ranging between 0.4 and 3.6% in various countries. Although the development of CRC was extensively studied, limited number of new therapies were developed in the last few years. Bevaci...

Full description

Bibliographic Details
Main Authors: Călin Căinap, Ovidiu-Vasile Bochiş, Cătălin Vlad, Raluca Popita, Patriciu Achimaş-Cadariu, Andrei Havasi, Andreea Vidrean, Alexandra Dranca, Andra Piciu, Anne-Marie Constantin, Tiberiu Tat, Maniu Dana, Ovidiu Crişan, Cosmin Vasile Cioban, Ovidiu Bălăcescu, Ovidiu Coza, Loredana Bălăcescu, Monica Mihaela Marta, Madalina Bota, Simona Căinap
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
colorectal
cancer
progression
bevacizumab
metastasis
double dose
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.487316/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.487316/full

Similar Items